Triflusal , 97% , 322-79-2

Synonym(s):
α,α,α-trifluoro-2,4-cresotic acid acetate;2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid;acetyl-4-trifluoromethylsalicylic acid;Drisgen;Triflusal

CAS NO.：322-79-2

Empirical Formula: C10H7F3O4

Molecular Weight: 248.16

MDL number: MFCD00866793

EINECS: 206-297-5

PRODUCT Properties

• Melting point: 120-122° (upon slow heating); 110-112° (upon quick heating)
• Boiling point: 316.0±42.0 °C(Predicted)
• Density: 1.433±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,2-8°C
• solubility: DMSO: >30mg/mL
• pka: 2.97±0.10(Predicted)
• form: powder
• color: white to off-white
• λmax: 297nm(H2O)(lit.)
• Merck: 14,9688

Description and Uses

Triflusal is an antiplatelet agent structurally related to the salicylates, but it is not derived from ASA. Triflusal and its metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or HTB) produce specic inhibition of platelet arachidonic acid metabolism (McNeely and Goa, 1998). A single 12-month open-label trial of Triflusal in 73 VaD patients (López-Pousa et al., 1997) showed fewer declines in MMSE scores in the active group compared with untreated subjects. More recently, Triflusal was used in patients with amnesic MCI; 257 patients were randomized to receive 900 mg of Triflusal or placebo for 18 months. Triflusal therapy was associated with a signicantly lower rate of conversion to dementia (Gómez-Isla et al., 2008).

An analog of Aspirin; inhibits platelet aggregation. Antithrombotic.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H317-H319-H335
• Precautionary statements: P261-P264-P280-P280-P304+P340+P312-P333+P313
• Hazard Codes: Xn
• Risk Statements: 22-36/37/38-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• RTECS: GP4250000
• HS Code: 2918.29.7500